OTCMNXEN
Market cap396kUSD
Dec 27, Last price
0.01USD
1D
-1.75%
1Q
-67.82%
Jan 2017
-16.42%
Name
Nexien Biopharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.34%
Rev. gr., 5y
%
Revenues
0k
Net income
-239k
L-33.93%
CFO
-64k
L-21.27%
Earnings
Feb 18, 2025
Profile
Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 283 | 564 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (283) | (564) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (239) | |||||||||
Tax Rate | ||||||||||
NOPAT | 239 | (283) | (564) | |||||||
Net income | (239) -33.93% | (362) -42.22% | (626) -66.61% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 2 | |||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 312 | 271 | 177 | |||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 197 | |||||||||
Net debt | 308 | 236 | 60 | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (64) | (82) | (75) | |||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 33 | 174 | ||||||||
FCF | 295,134,272 | (295,134,267) | (565) | |||||||
| Balance | ||||||||||
Cash | 4 | 35 | 117 | |||||||
Long term investments | ||||||||||
Excess cash | 4 | 35 | 117 | |||||||
Stockholders' equity | (11,527) | (11,238) | (10,877) | |||||||
Invested Capital | 11,478 | 295,145,258 | 10,936 | |||||||
ROIC | 0.00% | |||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 66,194 | 62,333 | 57,860 | |||||||
Price | 0.02 -52.73% | 0.04 | ||||||||
Market cap | 1,119 -49.80% | 2,228 | ||||||||
EV | 1,427 | 2,465 | ||||||||
EBITDA | (233) | (564) | ||||||||
EV/EBITDA | ||||||||||
Interest | 83 | 79 | 62 | |||||||
Interest/NOPBT | ||||||||||